However, therapeutic responses to XPO1 inhibitor monotherapy remain unsatisfactory17,18,22,23, suggesting that combination treatments are necessary to improve the cytotoxic effects of XPO1 inhibitors against tumor cells. This evidence concerns the gene XPO1 and neoplasm.